The following represents disclosure information provided by faculty of the educational and scientific sessions. The Committee have reviewed all presented disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm).
 
Maha Hussain
 
Employment - No Relationships to Disclose
 
Leadership - No Relationships to Disclose
 
Stock and Other Ownership Interests - No Relationships to Disclose
 
Honoraria - Academic CME; AstraZeneca; AstraZeneca; Bayer; Clinical Care Options; Great Debates and Updates; Medscape; Merck; Novartis; Research to Practice; Targeted Oncology
 
Consulting or Advisory Role - AstraZeneca; Bayer; Bayer; Convergent Therapeutics; GlaxoSmithKline; GlaxoSmithKline; Janssen; Merck; Novartis; Pfizer; Tempus
 
Speakers' Bureau - No Relationships to Disclose
 
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst)
 
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
 
Expert Testimony - No Relationships to Disclose
 
Travel, Accommodations, Expenses - No Relationships to Disclose
 
Other Relationship - No Relationships to Disclose
 
(OPTIONAL) Uncompensated Relationships - No Relationships to Disclose